Rubius Therapeutics, Inc. (RUBY) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
399 Binney Street
Cambridge, MA 02139
United States of America (the)
Phone
617 679 9600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
6
First IPO Date
July 18, 2018
| Name | Title | Pay | Year Born |
| Craig R. Jalbert | President, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director | 0 | 1962 |
| Marissa Hanify | Director of Corporation Communications | 0 | N/A |
Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.